LIFERIVER(SH:688317)2023-10-26 16:00Financial Performance - The company's operating revenue for Q3 2023 was ¥58,283,821.52, a decrease of 85.55% compared to the same period last year, and a decline of 89.10% year-to-date[5]. - The net profit attributable to shareholders for Q3 2023 was ¥3,021,706.56, down 97.99% year-on-year, with a year-to-date decline of 94.49%[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2023 was ¥1,190,472.83, a decrease of 99.18% compared to the previous year, and a decline of 95.98% year-to-date[5]. - The basic earnings per share for Q3 2023 was ¥0.02, down 97.47% year-on-year, with a year-to-date decline of 94.51%[6]. - Total operating revenue for the first three quarters of 2023 was CNY 205,201,872.85, a significant decrease from CNY 1,882,802,710.96 in the same period of 2022, representing a decline of approximately 89.1%[19]. - Net profit for the third quarter of 2023 was CNY 34,641,306.81, a decrease of approximately 94.5% compared to CNY 628,349,515.82 in the same quarter of 2022[20]. - The total equity attributable to shareholders was CNY 3,996,173,217.40, compared to CNY 4,200,411,657.40 in the previous year, showing a decrease of approximately 4.8%[18]. - The total comprehensive income for the third quarter of 2023 was CNY 25,136,286.38, down from CNY 614,364,651.67 in the same quarter of 2022, reflecting a decrease of about 95.9%[21]. Research and Development - The total R&D investment for Q3 2023 was ¥14,084,477.39, a decrease of 38.22% compared to the same period last year, and a year-to-date decline of 22.76%[6]. - R&D investment accounted for 24.17% of operating revenue in Q3 2023, an increase of 18.52 percentage points year-on-year[6]. - Research and development expenses for the first three quarters of 2023 were CNY 42,353,979.69, down from CNY 54,836,951.31 in the same period of 2022, indicating a reduction of about 22.7%[19]. Assets and Liabilities - The company's total assets at the end of the reporting period were ¥4,223,766,266.75, a decrease of 10.96% compared to the end of the previous year[6]. - The equity attributable to shareholders at the end of the reporting period was ¥3,996,173,217.40, down 4.86% year-on-year[6]. - The company's current assets totaled ¥3,401,779,972.87, down from ¥3,909,848,957.27, indicating a decrease of about 13%[16]. - The total liabilities of the company as of the third quarter of 2023 amounted to CNY 227,593,049.35, down from CNY 543,439,647.94 in the previous year, reflecting a reduction of about 58.1%[20]. - The total liabilities of the company were not explicitly stated, but accounts payable decreased significantly to ¥109,137,010.53 from ¥317,670,146.75, a reduction of about 65.6%[16]. - The company reported a significant drop in contract liabilities from ¥59,317,687.74 to ¥22,785,391.43, representing a decrease of approximately 61.6%[16]. Cash Flow - The net cash flow from operating activities for the year-to-date was negative, primarily due to a significant decline in sales revenue[10]. - Operating cash flow for the first nine months was negative at -145,253,368.09, compared to a positive cash flow of 473,382,062.50 in the same period last year[25]. - Total cash inflow from operating activities was 356,878,605.48, while cash outflow was 502,131,973.57, resulting in a net cash flow from operating activities of -145,253,368.09[25]. - Investment activities generated a net cash flow of -42,307,352.79, with cash inflow of 7,215,805.63 and outflow of 49,523,158.42[26]. - Financing activities resulted in a net cash flow of -233,158,750.37, with cash outflow for debt repayment and dividend distribution totaling 233,158,750.37[26]. - The cash and cash equivalents at the end of the period decreased to 2,758,032,313.85 from 3,147,723,751.88 at the beginning of the period[26]. Market and Demand - The company experienced a substantial decrease in demand for COVID-related business, impacting overall sales revenue and profitability[10]. - The company has not disclosed any new product developments or market expansion strategies in the current report[15].